TCGA-ZF-AA51-01A-21R-A39I-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 56.30749014
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.550
- INFLAMMATORY_RESPONSE+0.470
- IL6_JAK_STAT3_SIGNALING+0.450
- ANGIOGENESIS+0.430
- TNFA_SIGNALING_VIA_NFKB+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- KRAS_SIGNALING_UP+0.400
- COAGULATION+0.370
- IL2_STAT5_SIGNALING+0.360
- NOTCH_SIGNALING+0.340
Top 10 suppressed
- PROTEIN_SECRETION-0.420
- DNA_REPAIR-0.400
- OXIDATIVE_PHOSPHORYLATION-0.400
- MITOTIC_SPINDLE-0.350
- MYC_TARGETS_V1-0.350
- E2F_TARGETS-0.340
- G2M_CHECKPOINT-0.340
- UNFOLDED_PROTEIN_RESPONSE-0.310
- HEME_METABOLISM-0.300
- ANDROGEN_RESPONSE-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2d8d97e6-b599-4444-8e11-73adb55be0be | — | — | 0.892 |
| 2 | DRR168569 | — | — | 0.891 |
| 3 | R101 | — | — | 0.880 |
| 4 | MDT-AP-1108 | Med | Medulloblastoma | 0.879 |
| 5 | TCGA-A2-A0EP-01A-52R-A22U-07 | — | A | 0.876 |
| 6 | SRR1440082 | GTEX | — | 0.876 |
| 7 | f2903ac6-88e3-4653-a966-ab593fba51bf | — | — | 0.875 |
| 8 | TCGA-44-A47G-01A-21R-A24H-07 | — | cohortA1 | 0.874 |
| 9 | TCGA-49-AARO-01A-12R-A41B-07 | — | cohortA1 | 0.873 |
| 10 | SRR1316392 | GTEX | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.450 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.430 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.370 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.310 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.270 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.260 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.260 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.180 | Cobimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |
| MYOGENESIS | 0.110 | Inavolisib | — uncovered |